Abstract: AIM: To analyze the influencing factor of effect for treating postmenopausal osteoporosis with risedronate sodium capsules.METHODS: This is a randomized double-blind placebo-controlled clinical research.All patients were divided into two groups, trail group and control group.During 12 months, patients of trail group took risedronate sodium capsules orally every morning, patients of control group took placebo orally every morning, and at the same time all patients took calcichew D orally every night.Multiple linear regression analysis on influencing factor of effect including person's age, height, body weight, body mass index, menopause years, and therapeutic method.RESULTS: The therapeutic method was eventually conducted into the regression equation(P<0.05).CONCLUSION: Risedronate sodium capsule is the independent influencing factor for increasing bone mineral density(BMD), and the BMD has annual gain 0.041 g/cm²

Key words: risedronate sodium, osteoporosis, bone mineral density, multiple linear regression